MarketLens

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Arcturus Therapeutics Poised for a Massive Upside in 2026

5 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

5 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

3 months ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

5 months ago

Praxis Precision Medicines: Priced For Half Of What I Think It's Worth

Praxis Precision Medicines' stock is trading at half the analyst's estimated intrinsic value, based on pipeline prospects.

PRAX

Stock News•1 months ago

AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish

ATAI's BPL-003 advances to Phase 3 trials for treatment-resistant depression (TRD) with topline data expected by early 2029, while VLS-01 offers a nearer Q4 2026 catalyst.

ATAI

Stock News•2 months ago

The Next Great AI Revolution May Be Drug Delivery

NeOnc (NASDAQ:NTHI) is advancing proprietary drug delivery technologies and therapies specifically targeting aggressive brain cancers and CNS-related conditions. The company aims to address significan...

NTHI

Stock News•2 months ago

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Protagenic Therapeutics (OTCQB:PTIX) engaged Floyd Regulatory Strategic Consulting and Danforth Health to support the clinical development of its lead candidate, PT00114. These partnerships aim to acc...

PTIX